6.
McKimm-Breschkin J, Trivedi T, Hampson A, Hay A, Klimov A, Tashiro M
. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother. 2003; 47(7):2264-72.
PMC: 161875.
DOI: 10.1128/AAC.47.7.2264-2272.2003.
View
7.
Storms A, Gubareva L, Su S, Wheeling J, Okomo-Adhiambo M, Pan C
. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. Emerg Infect Dis. 2012; 18(2):308-11.
PMC: 3310472.
DOI: 10.3201/eid1802.111466.
View
8.
Matrosovich M, Matrosovich T, Garten W, Klenk H
. New low-viscosity overlay medium for viral plaque assays. Virol J. 2006; 3:63.
PMC: 1564390.
DOI: 10.1186/1743-422X-3-63.
View
9.
Sato M, Honzumi K, Sato T, Hashimoto K, Watanabe M, Miyazaki K
. Sequential influenza B viral load and susceptibility in children treated with oseltamivir and zanamivir. Pediatr Infect Dis J. 2014; 33(7):e168-72.
DOI: 10.1097/INF.0000000000000266.
View
10.
Neuzil K, Mellen B, Wright P, Mitchel Jr E, Griffin M
. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med. 2000; 342(4):225-31.
DOI: 10.1056/NEJM200001273420401.
View
11.
Whitley R, Boucher C, Lina B, Nguyen-Van-Tam J, Osterhaus A, Schutten M
. Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS). Clin Infect Dis. 2013; 56(9):1197-205.
DOI: 10.1093/cid/cis1220.
View
12.
Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K
. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004; 364(9436):759-65.
DOI: 10.1016/S0140-6736(04)16934-1.
View
13.
Sato M, Honzumi K, Sato T, Hashimoto K, Watanabe M, Miyazaki K
. Quantitative analysis of influenza A (H3N2) E119V and R292K variants in clinical specimens by real-time reverse transcription polymerase chain reaction. J Clin Virol. 2015; 68:97-103.
DOI: 10.1016/j.jcv.2015.05.018.
View
14.
Duan S, Boltz D, Li J, Oshansky C, Marjuki H, Barman S
. Novel genotyping and quantitative analysis of neuraminidase inhibitor resistance-associated mutations in influenza a viruses by single-nucleotide polymorphism analysis. Antimicrob Agents Chemother. 2011; 55(10):4718-27.
PMC: 3187000.
DOI: 10.1128/AAC.00316-11.
View
15.
Tamura D, Sugaya N, Ozawa M, Takano R, Ichikawa M, Yamazaki M
. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clin Infect Dis. 2011; 52(4):432-7.
PMC: 3062105.
DOI: 10.1093/cid/ciq183.
View
16.
van der Vries E, Anber J, van der Linden A, Wu Y, Maaskant J, Stadhouders R
. Molecular assays for quantitative and qualitative detection of influenza virus and oseltamivir resistance mutations. J Mol Diagn. 2013; 15(3):347-54.
DOI: 10.1016/j.jmoldx.2012.11.007.
View
17.
Sato M, Ito M, Suzuki S, Sakuma H, Takeyama A, Oda S
. Influenza viral load and peramivir kinetics after single administration and proposal of regimens for peramivir administration against resistant variants. Antimicrob Agents Chemother. 2014; 59(3):1643-9.
PMC: 4325767.
DOI: 10.1128/AAC.04263-14.
View
18.
Deyde V, Okomo-Adhiambo M, Sheu T, Wallis T, Fry A, Dharan N
. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antiviral Res. 2008; 81(1):16-24.
DOI: 10.1016/j.antiviral.2008.08.008.
View
19.
Takashita E, Ejima M, Itoh R, Miura M, Ohnishi A, Nishimura H
. A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013. Euro Surveill. 2014; 19(1).
DOI: 10.2807/1560-7917.es2014.19.1.20666.
View